Clinical trial · Interventional
Late Endocrine and Metabolic Consequences After Childhood Brain Tumor Treatment
Late Endocrine and Metabolic Consequences of Treatment of Primary Brain Tumors in Childhood
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This interventional study evaluates the late endocrine and metabolic consequences of treatment of primary brain tumors in childhood. Childhood brain tumor survivors are at increased risk of developing long-term complications such as hormonal deficiencies, obesity, impaired growth, dyslipidemia, and other metabolic disorders, which may significantly affect long-term health and quality of life. The aim of this study is to assess the prevalence and severity of endocrine and metabolic late effects in patients treated for brain tumors during childhood in Slovenia, and to identify associations with tumor localization, treatment modality, and physical performance. Participants undergo structured clinical follow-up examinations and targeted endocrine and metabolic assessments according to the study protocol. The results of this study may help identify individuals at increased risk and improve long-term follow-up strategies, prevention, and management of late treatment-related complications.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Brain Tumors | Childhood Brain Neoplasm | ALIAS | 0.90 |
| Endocrine Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endocrine and Metabolic Late Effects Assessment | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Late Effects Assessment Group
- description
- Participants treated for primary brain tumors in childhood undergo a structured follow-up assessment to evaluate late endocrine and metabolic complications. The study includes clinical examination, anthropometric measurements, laboratory endocrine and metabolic testing, and evaluation of physical competence. Outcomes are analyzed in relation to tumor location and previous treatment modalities.
- interventionNames
- Diagnostic Test: Endocrine and Metabolic Late Effects Assessment
Primary outcomes (1)
- measure
- Prevalence of Endocrine and Metabolic Late Complications
- timeFrame
- During a single assessment visit (up to 1 day)
- description
- Percentage of participants with at least one endocrine or metabolic late complication, defined as the presence of any endocrine disorder (growth hormone deficiency, hypothyroidism, adrenal insufficiency, hypogonadism) or any metabolic disorder (overweight/obesity defined by body mass index ≥25 kg/m², dyslipidemia defined by abnormal lipid profile, impaired glucose metabolism defined by fasting plasma glucose or HbA1c criteria), assessed by standardized clinical and laboratory evaluation.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * History of primary brain tumor diagnosed and treated in childhood * Completed treatment for primary brain tumor (surgery and/or radiotherapy and/or chemotherapy) * Patient is in follow-up care at the Institute of Oncology Ljubljana * Availability for clinical endocrine and metabolic assessment * Written informed consent provided by the participant or legal guardian (if applicable) Exclusion Criteria: * Active malignant disease requiring ongoing oncological treatment * Severe acute illness preventing participation in endocrine/metabolic evaluation * Inability to comply with study procedures or follow-up assessments * Refusal or inability to provide informed consent
References
Publications (0)
Data not yet available